Trial Profile
A Randomized Phase 3 Trial of ALIMTA and Cisplatin Versus GEMZAR and Cisplatin in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Sep 2019
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Pemetrexed (Primary) ; Cisplatin
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 11 Oct 2016 Results of pooled analysis of three phase III trials (JMDB, PARAMOUNT and JMII; n=1064) were presented at the 41st European Society for Medical Oncology Congress
- 11 Jun 2008 The expected completion date for this trial was 1 Mar 2008 instead of 1 Jun 2008 according to clinicaltrials.gov.
- 28 May 2008 Primary endpoint met; results to be reported in the Journal of Clinical Oncology, according to an Eli Lilly media release.